Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus hyperthermia in recurrent head and neck or bladder cancer
NL-OMON44022Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in head and neck squamous cell carcinoma (HNSCC) and bladder cancer (2 arms), sponsored by Erasmus MC. Primary endpoints: Recommended phase II dose and Toxicity. Started Jun 2016; status: recruiting.
02
Drugs
olaparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON44022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44022.